JANUMET XR (sitagliptin and metformin hydrochloride) by Merck & Co. is 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (dpp-4) inhibitor, and metformin extended-release, a member of the biguanide class. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
JANUMET XR is a fixed-dose combination tablet combining sitagliptin (a DPP-4 inhibitor) and extended-release metformin (a biguanide) for oral treatment of type 2 diabetes mellitus. Sitagliptin works by slowing the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon in a glucose-dependent manner, while metformin decreases hepatic glucose production and improves insulin sensitivity. The extended-release formulation allows for once-daily dosing, improving patient compliance. JANUMET XR represents a combination approach that addresses multiple pathways in type 2 diabetes pathophysiology.
2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin extended-release, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which exerts its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.…
Worked on JANUMET XR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMerck & Co. is hiring 8 roles related to this product
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
$392M Medicare spend — this is a commercially significant brand
JANUMET XR currently has zero open job postings linked to this product profile. The approaching LOE status suggests limited career expansion in product-specific roles; remaining opportunities likely center on managed decline brand management, regional sales support for formulary defense, and competitive intelligence versus generic alternatives. Pharmaceutical professionals on this product should prioritize expertise in generic transition strategies, payer negotiations, and lifecycle management.